The MHC class-II neoantigens may shape the tumor immunity and response to immunotherapy, indicating the ignored MHC-II neoantigens and CD4+ T cells as key factors that influence the response to immunotherapy (Alspach et al., 2019). This evidence concerns the gene CD4 and neoplasm.